Intra-Cellular Therapies Ownership | Who Owns Intra-Cellular Therapies?


OverviewForecastRevenueFinancialsChartTranscripts

Intra-Cellular Therapies Ownership Summary


Intra-Cellular Therapies is owned by 99.44% institutional investors, 2.33% insiders. Fmr is the largest institutional shareholder, holding 11.60% of ITCI shares. Fidelity Growth Compy Commingled Pl O is the top mutual fund, with 3.69% of its assets in Intra-Cellular Therapies shares.

ITCI Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockIntra-Cellular Therapies99.44%2.33%-1.77%
SectorHealthcare Stocks 47.31%8.01%44.69%
IndustrySpecialty & Generic Drug Manufacturers Stocks33.38%9.20%57.42%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Fmr11.24M11.60%$769.68M
Vanguard group9.61M9.92%$657.98M
Blackrock6.32M6.53%$432.97M
Wasatch advisors lp3.72M3.84%$254.66M
Jpmorgan chase3.44M3.55%$235.28M
Avoro capital advisors3.00M3.10%$205.47M
Invesco2.94M3.03%$201.18M
Bellevue group2.47M2.55%$169.26M
Norges bank1.94M2.01%$133.13M
State street1.80M1.86%$123.44M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Altium capital management lp193.00K5.39%$13.22M
Suvretta capital management1.57M3.94%$107.26M
First turn management347.34K3.87%$23.79M
Dcf advisers100.51K3.55%$6.88M
Silverarc capital management192.34K3.11%$13.17M
Artia global partners lp216.52K2.87%$14.83M
Perceptive advisors1.72M2.79%$117.56M
Bellevue group2.47M2.75%$169.26M
Avoro capital advisors3.00M2.74%$205.47M
Tang capital management300.00K2.09%$20.55M

Top Buyers

HolderShares% AssetsChange
Norges bank1.94M0.02%1.94M
Jpmorgan chase3.44M0.02%1.68M
Alyeska investment group1.39M0.55%1.14M
Westfield capital management co lp1.04M0.35%1.04M
Invesco2.94M0.04%864.37K

Top Sellers

HolderShares% AssetsChange
Blackrock6.32M0.01%-1.76M
Avidity partners management lp---600.00K
Macquarie group1.01M0.08%-451.11K
State street1.80M0.01%-438.44K
Wellington management group llp1.25M0.02%-408.97K

New Positions

HolderShares% AssetsChangeValue
Norges bank1.94M0.02%1.94M$133.13M
Westfield capital management co lp1.04M0.35%1.04M$71.43M
Hood river capital management487.52K0.69%487.52K$33.39M
Driehaus capital management215.44K0.14%215.44K$14.76M
Moody aldrich partners99.01K1.32%99.01K$6.78M

Sold Out

HolderChange
Sanctuary wealth management-1.00
Financial gravity asset management-1.00
Continuum advisory-6.00
Financial synergies wealth advisors-6.00
International assets investment management-12.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20243783.00%96,330,66610.68%991.21%21019.32%127-
Mar 31, 20243675.16%87,032,607-2.57%901.05%176-3.83%12711.40%
Dec 31, 202334915.95%89,328,8313.75%921.15%18312.96%11426.67%
Sep 30, 20233011.69%86,097,2812.30%891.15%162-1.82%9011.11%
Jun 30, 20232962.78%84,160,9960.64%881.14%16511.49%81-8.99%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Fidelity Growth Compy Commingled Pl O3.90M3.69%-95.00K
Fidelity Growth Compy Commingled Pl S3.89M3.67%-14.37K
Vanguard Total Stock Mkt Idx Inv3.20M3.02%-13.99K
Fidelity Growth Company Fund2.88M2.71%-45.39K
Vanguard Small Cap Index2.52M2.37%4.95K
BB Biotech AG Ord2.47M2.34%20.00K
Vanguard Institutional Extnd Mkt Idx Tr1.48M1.39%-22.20K
Vanguard Small Cap Growth Index Inv1.38M1.30%-3.79K
JPM US Mid Cap Growth-Composite1.32M1.25%137.29K
JPMorgan Mid Cap Growth I1.32M1.24%-

Recent Insider Transactions


DateNameRoleActivityValue
Nov 12, 2024Halstead Michael PresidentSell$548.18K
Nov 12, 2024Halstead Michael PresidentSell$149.79K
Nov 12, 2024Halstead Michael PresidentSell$1.34M
Nov 13, 2024Halstead Michael PresidentSell$1.18M
Nov 13, 2024Halstead Michael PresidentSell$475.10K

Insider Transactions Trends


DateBuySell
2024 Q4-5
2024 Q3-17
2024 Q2-3
2024 Q1-73
2023 Q4-5

ITCI Ownership FAQ


Who Owns Intra-Cellular Therapies?

Intra-Cellular Therapies shareholders are primarily institutional investors at 99.44%, followed by 2.33% insiders and -1.77% retail investors. The average institutional ownership in Intra-Cellular Therapies's industry, Specialty & Generic Drug Manufacturers Stocks, is 33.38%, which Intra-Cellular Therapies exceeds.

Who owns the most shares of Intra-Cellular Therapies?

Intra-Cellular Therapies’s largest shareholders are Fmr (11.24M shares, 11.60%), Vanguard group (9.61M shares, 9.92%), and Blackrock (6.32M shares, 6.53%). Together, they hold 28.04% of Intra-Cellular Therapies’s total shares outstanding.

Does Blackrock own Intra-Cellular Therapies?

Yes, BlackRock owns 6.53% of Intra-Cellular Therapies, totaling 6.32M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 432.97M$. In the last quarter, BlackRock decreased its holdings by -1.756M shares, a -21.74% change.

Who is Intra-Cellular Therapies’s biggest shareholder by percentage of total assets invested?

Altium capital management lp is Intra-Cellular Therapies’s biggest shareholder by percentage of total assets invested, with 5.39% of its assets in 193K Intra-Cellular Therapies shares, valued at 13.22M$.

Who is the top mutual fund holder of Intra-Cellular Therapies shares?

Fidelity Growth Compy Commingled Pl O is the top mutual fund holder of Intra-Cellular Therapies shares, with 3.69% of its total shares outstanding invested in 3.9M Intra-Cellular Therapies shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools